Goldman Sachs’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$145M Sell
187,600
-8,600
-4% -$6.58M 0.02% 839
2025
Q4
$151M Sell
196,200
-67,000
-25% -$45.5M 0.02% 758
2025
Q3
$148M Sell
263,200
-6,200
-2% -$3.51M 0.02% 735
2025
Q2
$141M Sell
269,400
-12,200
-4% -$6.81M 0.02% 715
2025
Q1
$179M Sell
281,600
-78,800
-22% -$54.2M 0.03% 551
2024
Q4
$257M Buy
360,400
+72,000
+25% +$60.4M 0.04% 420
2024
Q3
$303M Buy
288,400
+30,900
+12% +$34.4M 0.05% 376
2024
Q2
$271M Buy
257,500
+216,500
+528% +$210M 0.05% 419
2024
Q1
$39.5M Sell
41,000
-1,900
-4% -$1.81M 0.01% 1315
2023
Q4
$37.7M Buy
42,900
+18,200
+74% +$15M 0.01% 1383
2023
Q3
$20.3M Sell
24,700
-17,000
-41% -$13.4M ﹤0.01% 1785
2023
Q2
$30M Sell
41,700
-17,000
-29% -$13.1M 0.01% 1505
2023
Q1
$48.2M Sell
58,700
-42,100
-42% -$31.8M 0.01% 1092
2022
Q4
$72.7M Buy
100,800
+89,800
+816% +$66.3M 0.02% 898
2022
Q3
$7.58M Buy
11,000
+4,200
+62% +$2.64M ﹤0.01% 2769
2022
Q2
$4.02M Sell
6,800
-11,900
-64% -$7.74M ﹤0.01% 3363
2022
Q1
$13.1M Buy
18,700
+12,400
+197% +$7.84M ﹤0.01% 2425
2021
Q4
$3.98M Buy
6,300
+2,600
+70% +$1.6M ﹤0.01% 3634
2021
Q3
$2.24M Buy
+3,700
New +$2.3M ﹤0.01% 4092
2021
Q1
Sell
-21,000
Closed -$10.1M 6300
2020
Q4
$10.1M Buy
21,000
+11,800
+128% +$6.37M ﹤0.01% 2454
2020
Q3
$5.15M Buy
9,200
+8,100
+736% +$4.91M ﹤0.01% 2871
2020
Q2
$686K Sell
1,100
-9,600
-90% -$5.45M ﹤0.01% 4201
2020
Q1
$5.22M Buy
10,700
+4,500
+73% +$1.86M ﹤0.01% 2599
2019
Q4
$2.33M Buy
+6,200
New +$2.09M ﹤0.01% 3534
2019
Q3
Sell
-17,500
Closed -$5.48M 5345
2019
Q2
$5.48M Buy
17,500
+400
+2% +$133K ﹤0.01% 2785
2019
Q1
$7.02M Buy
17,100
+10,400
+155% +$4.28M ﹤0.01% 2714
2018
Q4
$2.5M Sell
6,700
-3,800
-36% -$1.39M ﹤0.01% 3394
2018
Q3
$4.24M Sell
10,500
-5,900
-36% -$2.25M ﹤0.01% 3106
2018
Q2
$5.66M Sell
16,400
-6,500
-28% -$2.03M ﹤0.01% 2876
2018
Q1
$7.89M Sell
22,900
-61,200
-73% -$21.3M ﹤0.01% 2536
2017
Q4
$31.6M Sell
84,100
-14,000
-14% -$5.67M 0.01% 1608
2017
Q3
$43.9M Sell
98,100
-1,500
-2% -$714K 0.01% 1385
2017
Q2
$48.9M Sell
99,600
-9,700
-9% -$4.24M 0.01% 1254
2017
Q1
$42.4M Sell
109,300
-189,400
-63% -$70.2M 0.01% 1338
2016
Q4
$110M Buy
298,700
+169,400
+131% +$64.4M 0.03% 715
2016
Q3
$52M Buy
129,300
+4,100
+3% +$1.64M 0.02% 1176
2016
Q2
$43.7M Buy
125,200
+2,700
+2% +$1.04M 0.01% 1215
2016
Q1
$44.2M Buy
122,500
+56,900
+87% +$23.4M 0.01% 1166
2015
Q4
$35.6M Buy
65,600
+15,100
+30% +$8.18M 0.01% 1360
2015
Q3
$23.5M Buy
50,500
+5,400
+12% +$2.9M 0.01% 1600
2015
Q2
$23M Buy
45,100
+3,200
+8% +$1.56M 0.01% 1687
2015
Q1
$18.9M Sell
41,900
-65,300
-61% -$27.7M 0.01% 1795
2014
Q4
$44M Buy
107,200
+76,200
+246% +$30M 0.01% 1210
2014
Q3
$11.2M Sell
31,000
-2,800
-8% -$938K ﹤0.01% 2271
2014
Q2
$9.55M Sell
33,800
-18,700
-36% -$5.54M ﹤0.01% 2404
2014
Q1
$15.8M Sell
52,500
-18,900
-26% -$5.82M 0.01% 1967
2013
Q4
$19.7M Sell
71,400
-11,400
-14% -$3.28M 0.01% 1753
2013
Q3
$25.9M Buy
82,800
+26,900
+48% +$7.08M 0.01% 1404
2013
Q2
$12.6M Buy
+55,900
New +$13M ﹤0.01% 1897

Other funds holding REGN

Goldman Sachs's REGN Position: Q1 2026 in Review

Goldman Sachs increased its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, buying an estimated $156M and bringing the position to 1,300,558 shares worth $1B. The position accounts for 0.12% of the portfolio, ranked #168.

Goldman Sachs first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Goldman Sachs held 1,300,558 shares of Regeneron Pharmaceuticals worth $1B as of Q1 2026.
  • Goldman Sachs bought 203,231 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $156M.
  • Regeneron Pharmaceuticals made up 0.12% of Goldman Sachs's portfolio in Q1 2026, its #168 holding.
  • Goldman Sachs first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.